Siponimod Slows Physical Disability Progression and Decline in Cognitive Processing Speed in SPMS Patients with Active Disease: A Post Hoc Analysis of the EXPAND Study

被引：0
|
作者：
Gold, R. [1 ]
Kappos, L. [2 ,3 ,4 ,5 ,6 ]
Benedict, R. H. B. [7 ]
Bar-or, A. [8 ,9 ]
Vermersch, P. [10 ]
Giovannoni, G. [11 ]
Fox, R. J. [12 ]
Hach, T. [13 ]
Ritter, S. [14 ]
Rouyrre, N. [13 ]
Karlsson, G. [13 ]
Cree, B. A. C. [15 ]
机构：
[1] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany
[2] Univ Hosp, Neurol Clin & Policlin, Dept Med, Basel, Switzerland
[3] Univ Hosp, Neurol Clin & Policlin, Dept Clin Res, Basel, Switzerland
[4] Univ Hosp, Neurol Clin & Policlin, Dept Biomed, Basel, Switzerland
[5] Univ Hosp, Neurol Clin & Policlin, Dept Biomed Engn, Basel, Switzerland
[6] Univ Basel, Basel, Switzerland
[7] SUNY Buffalo, Dept Neurol, Buffalo, NY USA
[8] Univ Penn, Perelman Sch Med, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA 19104 USA
[9] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA
[10] Univ Lille, CHU Lille, FHU Imminent, INSERM,U995, Lille, France
[11] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England
[12] Cleveland Clin, Neurol Inst, Mellen Ctr Treatment & Res Multiple Sclerosis, Cleveland, OH 44106 USA
[13] Novartis Pharma AG, Basel, Switzerland
[14] Novartis Pharmaceut, E Hanover, NJ USA
[15] Univ Calif San Francisco, Dept Neurol, UCSF Weill Inst Neurosci, San Francisco, CA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR2118
引用
收藏
页码：328 / 329
页数：2
相关论文
共 26 条
  • [1] COGNITIVE PROCESSING SPEED PREDICTS DISEASE PROGRESSION IN SPMS: POST HOC ANALYSIS FROM THE EXPAND STUDY
    Penner, Iris-Katharina
    Giovannoni, Gavin
    Chitnis, Tanuja
    Vermesch, Patrick
    Arnould, Sophie
    DeLasHeras, Virginia
    Karlsson, Goeril
    Piani-Meier, Daniela
    Kappos, Ludwig
    Benedict, Ralph
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [2] Effect of siponimod on cognitive processing speed in spms patients with active and non-active disease
    Penner, I. -K.
    Giovannoni, G.
    Cree, B. A. C.
    Fox, R.
    Bar-Or, A.
    Gold, R.
    Vermersch, P.
    Hach, T.
    Goeril, K.
    Ritter, S.
    Rouyrre, N.
    Piani-Meier, D.
    Benedict, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 502 - 502
  • [3] Siponimod improves cognitive processing speed in patients with SPMS: Results from Phase 3 EXPAND Study
    Benedict, R. H.
    Cree, B.
    Tomic, D.
    Fox, R.
    Giovannoni, G.
    Bar-or, A.
    Gold, R.
    Vermersch, P.
    Pohlmann, H.
    Karlsson, G.
    Dahlke, F.
    Kappos, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 432 - 432
  • [4] Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study
    Hua, Le H.
    Bar-Or, Amit
    Cohan, Stanley L.
    Lublin, Fred
    Coyle, Patricia K.
    Cree, Bruce A. C.
    Meng, Xiangyi
    Su, Wendy
    Cox, Gina Mavrikis
    Fox, Robert J.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 75
  • [5] EFFECT OF SIPONIMOD ON DISABILITY PROGRESSION MEASURED BY AMBULATION SCORE: POST HOC ANALYSIS OF EXPAND
    D'Souza, Marcus
    Giovannoni, Gavin
    Vermersch, Patrick
    Maca, Jeff
    Ansari, Soudeh
    Karlsson, Goeril
    Piani-Meier, Daniele
    Kappos, Ludwig
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [6] Sustained reduction of disability and cognitive decline with long-term siponimod treatment in patients with active spms: expand data up to 5 years
    Giovannoni, G.
    Kappos, L.
    Fox, R.
    Vermersch, P.
    Cree, B. A. C.
    Benedict, R.
    Bar-Or, A.
    Rouyrre, N.
    Piani-Meier, D.
    Hach, T.
    Ritter, S.
    Kilaru, A.
    Dahlke, F.
    Karlsson, G.
    Gold, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 235 - 235
  • [7] Siponimod affects disability progression in SPMS patients independent of relapse activity: results from the phase III EXPAND study
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Vermersch, P.
    Bar-Or, A.
    Gold, R.
    Tomic, D.
    Magnusson, B.
    Rouyrre, N.
    Meier, D. Piani
    Karlsson, G.
    Dahlke, F.
    Kappos, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 70 - 71
  • [8] Analyses Of The Effect Of Disease Duration On The Efficacy And Safety Of Siponimod In Patients With Active SPMS From The Expand Study
    Bar-Or, A.
    Cohan, S. L.
    Coyle, P. K.
    Lublin, F. D.
    Meng, X.
    Su, W.
    Cree, B. A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 29 - 30
  • [9] Analyses of the Effect of Disease Duration on the Efficacy and Safety of Siponimod in Patients with Active SPMS from the Phase 3 EXPAND Study
    Cohan, Stanley L.
    Bar-Or, Amit
    Coyle, Patricia K.
    Lublin, Fred D.
    Meng, Xiangyi
    Su, Wendy
    Cree, Bruce A. C.
    [J]. NEUROLOGY, 2021, 96 (15)
  • [10] Does Cognitive Impairment Predict Physical Disability Progression? Evidence from EXPAND, a Phase 3 Long-Term SPMS Study
    Penner, I.
    Giovannoni, G.
    Chitnis, T.
    Vermersch, P.
    Arnould, S.
    Doerken, S.
    Ansari, S.
    Maca, J.
    DeLasHeras, V.
    Karlsson, G.
    Piani-Meier, D.
    Kappos, L.
    Benedict, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 142 - 142
123